Clinical Trial

Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2024 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is designed to comprehensively evaluate the HER2 positive recurrent/metastatic breast cancer patients in the real world who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab, including basic characteristics, efficacy and safety. The results of this study are helpful to further understand the efficacy and safety of HER2 positive patients with recurrent/metastatic breast cancer who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab in the first line, and help clinical decision-making.
Trial Details
NCT Number NCT06578299
Lead Sponsor Fudan University
Conditions Breast Cancer Stage IV
Enrollment 100 participants
Start Date 2024-08-30
Primary Completion 2026-03-30 (estimated)
Study Completion 2027-08-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-29